{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:48:44Z","timestamp":1776127724925,"version":"3.50.1"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Multiple myeloma is a plasma cell malignancy evolving in the bone marrow and leading to end organ damage such as bone lesions, cytopenias, and kidney failure. This review delineates recent advances in the molecular mechanisms leading to tumor progression in multiple myeloma. Two different aspects enable tumor expansion: cell autonomous through genomic alterations in the tumor clone and noncell autonomous deregulations in the bone marrow tumor microenvironment. These alterations provide the framework for the continuous progression of multiple myeloma from early precursor conditions such as monoclonal gammopathy of undetermined significance and smoldering multiple myeloma to overt multiple myeloma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In this review, we discuss recent findings in the genomic alterations that occur in the tumor clone such as somatic genomic mutations, copy number variation and chromosomal translocation, and delineate noncell autonomous deregulations in which tumor cells take advantage of a permissive microenvironment to further proliferate. The latter compartment includes interaction with bone marrow stromal cells, osteoblasts, osteoclasts, and immune escape.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Understanding the mechanisms that lead tumor progression from early stages to overt multiple myeloma could guide to more effective therapies and therefore prevent disease progression.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/moh.0000000000000259","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T12:12:34Z","timestamp":1461240754000},"page":"426-433","source":"Crossref","is-referenced-by-count":40,"title":["Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma"],"prefix":"10.1097","volume":"23","author":[{"given":"Salomon","family":"Manier","sequence":"first","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawara","family":"Kawano","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo M.","family":"Roccaro","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Aldo M. Roccaro and Irene M. Ghobrial are co-senior authors."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Aldo M. Roccaro and Irene M. Ghobrial are co-senior authors."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/0021-9681(58)90039-0","article-title":"The natural history of cancer","volume":"8","author":"Foulds","year":"1958","journal-title":"J Chronic Dis"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.21913","article-title":"Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Rajkumar","year":"2011","journal-title":"Am J Hematol"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/asheducation-2013.1.478","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies","volume":"2013","author":"Landgren","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-065X.2012.01124.x","article-title":"Germinal center selection and the development of memory B and plasma cells","volume":"247","author":"Shlomchik","year":"2012","journal-title":"Immunol Rev"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-62703-269-8_1","article-title":"Origin and pathogenesis of B cell lymphomas","volume":"971","author":"Seifert","year":"2013","journal-title":"Methods Mol Biol"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood.V87.2.746.bloodjournal872746","article-title":"Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance","volume":"87","author":"Sahota","year":"1996","journal-title":"Blood"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2002-09-2825","article-title":"Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma","volume":"101","author":"Zojer","year":"2003","journal-title":"Blood"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature09650","article-title":"Genetic variegation of clonal architecture and propagating cells in leukaemia","volume":"469","author":"Anderson","year":"2011","journal-title":"Nature"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/8816","article-title":"Evolution of neoplastic cell lineages in Barrett oesophagus","volume":"22","author":"Barrett","year":"1999","journal-title":"Nat Genet"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3324\/haematol.2008.004440","article-title":"Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/leu.2012.128","article-title":"SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status","volume":"26","author":"Lopez-Corral","year":"2012","journal-title":"Leukemia"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/sj.leu.2401041","article-title":"Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases","volume":"12","author":"Smadja","year":"1998","journal-title":"Leukemia"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2402797","article-title":"Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma","volume":"17","author":"Debes-Marun","year":"2003","journal-title":"Leukemia"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood-2005-02-0761","article-title":"A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS","volume":"106","author":"Chng","year":"2005","journal-title":"Blood"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Smadja","year":"2001","journal-title":"Blood"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood-2014-07-584268","article-title":"Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations","volume":"125","author":"Pawlyn","year":"2015","journal-title":"Blood"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/14622416.6.6.563","article-title":"Genomics in multiple myeloma: biology and clinical implications","volume":"6","author":"Chng","year":"2005","journal-title":"Pharmacogenomics"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.leu.2403518","article-title":"Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma","volume":"18","author":"Kaufmann","year":"2004","journal-title":"Leukemia"},{"key":"R32-20230917","first-page":"4546","article-title":"14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome","volume":"59","author":"Avet-Loiseau","year":"1999","journal-title":"Cancer Res"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","article-title":"High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood-2006-02-005496","article-title":"Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma","volume":"108","author":"Walker","year":"2006","journal-title":"Blood"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","article-title":"The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells","volume":"17","author":"Lopez-Corral","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"R43-20230917","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/cr.2014.26","article-title":"Bone's dark side: mutated osteoblasts implicated in leukemia","volume":"24","author":"Schajnovitz","year":"2014","journal-title":"Cell Res"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature12883","article-title":"Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts","volume":"506","author":"Kode","year":"2014","journal-title":"Nature"},{"key":"R45-20230917","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Azab","year":"2009","journal-title":"Blood"},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood-2009-01-199281","article-title":"RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma","volume":"114","author":"Azab","year":"2009","journal-title":"Blood"},{"key":"R47-20230917","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol Rev"},{"key":"R48-20230917","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"key":"R49-20230917","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood-2013-08-524025","article-title":"Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells","volume":"123","author":"Tanno","year":"2014","journal-title":"Blood"},{"key":"R50-20230917","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J Clin Invest"},{"key":"R51-20230917","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","article-title":"CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation","volume":"12","author":"Roccaro","year":"2015","journal-title":"Cell Rep"},{"key":"R52-20230917","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of endothelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"R53-20230917","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0037-1963(01)90020-4","article-title":"Myeloma bone disease","volume":"38","author":"Callander","year":"2001","journal-title":"Semin Hematol"},{"key":"R54-20230917","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/SPC.0000000000000090","article-title":"Role of osteocytes in multiple myeloma bone disease","volume":"8","author":"Delgado-Calle","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"key":"R55-20230917","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/10428194.2013.820288","article-title":"Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease","volume":"55","author":"Kristensen","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"(Suppl 2)","key":"R56-20230917","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S0049-3848(14)50017-5","article-title":"Microenvironment and multiple myeloma spread","volume":"133","author":"Ribatti","year":"2014","journal-title":"Thromb Res"},{"key":"R57-20230917","doi-asserted-by":"crossref","first-page":"157496","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"R58-20230917","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"R59-20230917","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"R60-20230917","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"R61-20230917","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"J Clin Invest"},{"key":"R62-20230917","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","article-title":"Engineered nanomedicine for myeloma and bone microenvironment targeting","volume":"111","author":"Swami","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R63-20230917","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"R64-20230917","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2001.19.15.3562","article-title":"Biology of osteoclast activation in cancer","volume":"19","author":"Roodman","year":"2001","journal-title":"J Clin Oncol"},{"key":"R65-20230917","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"key":"R66-20230917","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474086.2013.874943","article-title":"Management of bone disease in multiple myeloma","volume":"7","author":"Terpos","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"R67-20230917","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"R68-20230917","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0093-7754(01)90024-7","article-title":"Angiogenesis in multiple myeloma","volume":"28","author":"Rajkumar","year":"2001","journal-title":"Semin Oncol"},{"key":"R69-20230917","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0093-7754(01)90025-9","article-title":"Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis","volume":"28","author":"Munshi","year":"2001","journal-title":"Semin Oncol"},{"key":"R70-20230917","first-page":"2210","article-title":"Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R71-20230917","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cyto.2007.11.017","article-title":"Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents","volume":"41","author":"Cibeira","year":"2008","journal-title":"Cytokine"},{"key":"R72-20230917","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/sj.bmt.1704555","article-title":"Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy","volume":"34","author":"Kumar","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"R73-20230917","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1440-1827.2004.01622.x","article-title":"Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment","volume":"54","author":"Du","year":"2004","journal-title":"Pathol Int"},{"key":"R74-20230917","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/leu.2013.268","article-title":"Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial","volume":"28","author":"Bhutani","year":"2014","journal-title":"Leukemia"},{"key":"R75-20230917","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2016.3","article-title":"Targeting vasculogenesis to prevent progression in multiple myeloma","author":"Moschetta","year":"2016","journal-title":"Leukemia"},{"key":"R76-20230917","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J Clin Invest"},{"key":"R77-20230917","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1196\/annals.1358.004","article-title":"Immune response to premalignancy: insights from patients with monoclonal gammopathy","volume":"1062","author":"Dhodapkar","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"R78-20230917","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"R79-20230917","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J Immunother"},{"key":"R80-20230917","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R81-20230917","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.4049\/jimmunol.1202005","article-title":"Programmed death receptor-1\/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma","volume":"190","author":"Kearl","year":"2013","journal-title":"J Immunol"}],"container-title":["Current Opinion in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00062752-201607000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T06:07:28Z","timestamp":1694930848000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00062752-201607000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/moh.0000000000000259","relation":{},"ISSN":["1065-6251","1531-7048"],"issn-type":[{"value":"1065-6251","type":"print"},{"value":"1531-7048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}